328 related articles for article (PubMed ID: 29293566)
1. High human papillomavirus (HPV) prevalence in South African adolescents and young women encourages expanded HPV vaccination campaigns.
Mbulawa ZZA; van Schalkwyk C; Hu NC; Meiring TL; Barnabas S; Dabee S; Jaspan H; Kriek JM; Jaumdally SZ; Muller E; Bekker LG; Lewis DA; Dietrich J; Gray G; Passmore JS; Williamson AL
PLoS One; 2018; 13(1):e0190166. PubMed ID: 29293566
[TBL] [Abstract][Full Text] [Related]
2. High human papillomavirus prevalence among females attending high school in the Eastern Cape Province of South Africa.
Mbulawa ZZA; Somdyala NI; Mabunda SA; Williamson AL
PLoS One; 2021; 16(6):e0253074. PubMed ID: 34143816
[TBL] [Abstract][Full Text] [Related]
3. Patterns of prevalent HPV and STI co-infections and associated factors among HIV-negative young Western Cape, South African women: the EVRI trial.
Menezes LJ; Pokharel U; Sudenga SL; Botha MH; Zeier M; Abrahamsen ME; Glashoff RH; Engelbrecht S; Schim van der Loeff MF; van der Laan LE; Kipping S; Taylor D; Giuliano AR
Sex Transm Infect; 2018 Feb; 94(1):55-61. PubMed ID: 28490581
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trial.
Six L; Leodolter S; Sings HL; Barr E; Haupt R; Joura EA
Wien Klin Wochenschr; 2008; 120(21-22):666-71. PubMed ID: 19116707
[TBL] [Abstract][Full Text] [Related]
5. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study.
Chow EPF; Tabrizi SN; Fairley CK; Wigan R; Machalek DA; Garland SM; Cornall AM; Atchison S; Hocking JS; Bradshaw CS; Balgovind P; Murray GL; Chen MY
Lancet Infect Dis; 2021 Oct; 21(10):1448-1457. PubMed ID: 34043963
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa.
Michaeli DT; Stoycheva S; Marcus SM; Zhang W; Michaeli JC; Michaeli T
Clin Drug Investig; 2022 Apr; 42(4):333-343. PubMed ID: 35294726
[TBL] [Abstract][Full Text] [Related]
8. Monitoring human papillomavirus prevalence among young Australian women undergoing routine chlamydia screening.
Shilling H; Murray G; Brotherton JML; Hawkes D; Saville M; Sivertsen T; Chambers I; Roberts J; Farnsworth A; Garland SM; Hocking JS; Kaldor J; Guy R; Atchison S; Costa AM; Molano M; Machalek DA
Vaccine; 2020 Jan; 38(5):1186-1193. PubMed ID: 31767467
[TBL] [Abstract][Full Text] [Related]
9. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
[TBL] [Abstract][Full Text] [Related]
10. Distribution of Human Papillomavirus (HPV) Genotypes in HIV-Negative and HIV-Positive Women with Cervical Intraepithelial Lesions in the Eastern Cape Province, South Africa.
Taku O; Mbulawa ZZA; Phohlo K; Garcia-Jardon M; Businge CB; Williamson AL
Viruses; 2021 Feb; 13(2):. PubMed ID: 33670231
[TBL] [Abstract][Full Text] [Related]
11. Prevalent human papillomavirus infection increases the risk of HIV acquisition in African women: advancing the argument for human papillomavirus immunization.
Liu G; Mugo NR; Brown ER; Mgodi NM; Chirenje ZM; Marrazzo JM; Winer RL; Mansoor L; Palanee-Phillips T; Siva SS; Naidoo L; Jeenarain N; Gaffoor Z; Nair GL; Selepe P; Nakabiito C; Mkhize B; Mirembe BG; Taljaard M; Panchia R; Baeten JM; Balkus JE; Hladik F; Celum CL; Barnabas RV
AIDS; 2022 Feb; 36(2):257-265. PubMed ID: 34172672
[TBL] [Abstract][Full Text] [Related]
12. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus prevalence in South African women and men according to age and human immunodeficiency virus status.
Mbulawa ZZ; Coetzee D; Williamson AL
BMC Infect Dis; 2015 Oct; 15():459. PubMed ID: 26502723
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal assessment of nonavalent vaccine HPV types in a sample of sexually active African American women from ten U.S. Cities.
Madhivanan P; Krupp K; Coudray M; Colbert B; Ruiz-Perez D; Cui H; Bokulich N; Narasimhan G; Mathee K; Cook RL; Schwebke J; Roe D
Vaccine; 2021 Aug; 39(34):4810-4816. PubMed ID: 34294478
[TBL] [Abstract][Full Text] [Related]
15. High-risk human papillomavirus prevalence among South African women diagnosed with other STIs and BV.
Qulu W; Mtshali A; Osman F; Ndlela N; Ntuli L; Mzobe G; Naicker N; Garrett N; Rompalo A; Mindel A; Ngcapu S; Liebenberg L
PLoS One; 2023; 18(11):e0294698. PubMed ID: 38032961
[TBL] [Abstract][Full Text] [Related]
16. High HIV, HPV, and STI prevalence among young Western Cape, South African women: EVRI HIV prevention preparedness trial.
Giuliano AR; Botha MH; Zeier M; Abrahamsen ME; Glashoff RH; van der Laan LE; Papenfuss M; Engelbrecht S; Schim van der Loeff MF; Sudenga SL; Torres BN; Kipping S; Taylor D
J Acquir Immune Defic Syndr; 2015 Feb; 68(2):227-35. PubMed ID: 25415290
[TBL] [Abstract][Full Text] [Related]
17. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
[TBL] [Abstract][Full Text] [Related]
18. The prevalence of human papillomavirus infections and associated risk factors in men-who-have-sex-with-men in Cape Town, South Africa.
Müller EE; Rebe K; Chirwa TF; Struthers H; McIntyre J; Lewis DA
BMC Infect Dis; 2016 Aug; 16(1):440. PubMed ID: 27549219
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction.
Shilling H; Garland SM; Atchison S; Cornall AM; Brotherton JML; Bateson D; McNamee K; Kaldor JM; Hocking JS; Chen MY; Fairley CK; McNulty A; Bell C; Marshall L; Ooi C; Skinner SR; Murray G; Molano M; Tabrizi S; Machalek DA
Vaccine; 2021 Aug; 39(34):4856-4863. PubMed ID: 34281743
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
